Hot Features
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therape... Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.246 | 0.45690936107 | 53.84 | 56.07 | 53.5 | 6422553 | 55.19080802 | CS |
| 4 | 2.796 | 5.45135503997 | 51.29 | 56.07 | 49.2775 | 4398222 | 53.39014983 | CS |
| 12 | 8.146 | 17.7318241184 | 45.94 | 56.07 | 44.73 | 3466928 | 50.22589911 | CS |
| 26 | 14.636 | 37.1001267427 | 39.45 | 56.07 | 37.83 | 3641232 | 45.45717707 | CS |
| 52 | 20.956 | 63.2538484757 | 33.13 | 56.07 | 32.85 | 3754232 | 40.82896884 | CS |
| 156 | 20.636 | 61.692077728 | 33.45 | 56.07 | 24.05 | 3265166 | 33.86295473 | CS |
| 260 | 11.186 | 26.0745920746 | 42.9 | 56.07 | 24.05 | 2755470 | 35.56486587 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.